Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATINUM platform study in uncomplicated Plasmodium falciparum malaria
PACTR202302602361661Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2 trial of INE963, cipargamin, ganaplacide + lumefantrine-SDF and lumefantrine in malaria and Falciparum malaria (PF) (9 cohorts), sponsored by Novartis. Started Sep 2023; status: recruiting.
02
Drugs
INE963cipargaminganaplacide + lumefantrine-SDFlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR202302602361661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302602361661.